High materiality8/10
Kymera Therapeutics price target raised to $129 from $106 at Canaccord
Why it may matterVerify against the original reporting
Raising target indicates improving outlook; bullish.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Canaccord Genuity raises KYMR target to $129; current price $116.46.
- Canaccord Genuity raises KYMR target to $129; price $116.46.
Key facts
- 01
Target: $129
- 02
Posted price: $116.46
- 03
Analyst firm: Canaccord Genuity
- 04
Analyst: Edward Nash
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.